Category Archives: Platelet Rich Plasma Injections


Stem Cell Clinic > Platelet Rich Plasma Injections

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

By Platelet Rich Plasma Injections

FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the fiscal year ended December 31, 2024, and highlighted clinical updates and business progress.

See the rest here:
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

By Platelet Rich Plasma Injections

MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results and provide a business update for its first quarter 2025 ended February 28 on Wednesday, April 9, 2025, at 8:30 a.m. ET.

Go here to see the original:
Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

Praxis Precision Medicines to Participate in Upcoming April Conferences

By Platelet Rich Plasma Injections

BOSTON, April 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences this April:

Read this article:
Praxis Precision Medicines to Participate in Upcoming April Conferences

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN)…

By Platelet Rich Plasma Injections

Oral Plenary Presentation on Tuesday, April 8 Features Phase 3 Data for ANX005, the First Potential Targeted Therapy for GBS, Showing Rapid and Durable Benefit Across Clinical Measures and Time Points

Read more from the original source:
Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN)...

Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

By Platelet Rich Plasma Injections

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the status of its products in relation to the U.S. Government’s announcement on tariffs for imported products. Mesoblast believes that its allogeneic cellular products, including Ryoncil® and Revascor®, will not be subject to the tariffs.

See the original post:
Mesoblast Allogeneic Cell Therapy Products Are Designated ‘U.S. Country of Origin’ and Not Subject to U.S. Tariffs

New LabTAG Add-On Streamlines Laboratory Labeling with Dymo® LabelWriter™ 5-Series and eLabNext Integration

By Platelet Rich Plasma Injections

BOSTON, April 04, 2025 (GLOBE NEWSWIRE) --  GA International, a global leader in laboratory identification solutions, under its LabTAG brand, announced today that its DYMO® LabelWriter™ 5-Series Printing Kits are now compatible with eLabNext’s Digital Lab Platform (DLP) — an intuitive and flexible system for collecting, managing, and analyzing laboratory information.

See the rest here:
New LabTAG Add-On Streamlines Laboratory Labeling with Dymo® LabelWriter™ 5-Series and eLabNext Integration

←